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i.org/1regarding choice of P2Y12 inhibitor and timing of treatment initiation and is usually
dictated by institutional or even individual operator preference. Limited data are available
on the actual patterns of P2Y12 inhibitor use in contemporary practice in the United States.
We used electronic medical records from the Cerner “Health Facts” database of adults who
underwent coronary angiography with or without percutaneous coronary intervention
(PCI) from January 2008 to June 2013 and who received a loading dose of clopidogrel,
prasugrel, or ticagrelor at any time from 48 hours before the start of procedure up to
6 hours after. Timing of P2Y12 inhibitor administration was categorized as >2 hours before,
0 to 2 hours before (pretreatment groups), or after the start of procedure. Results were also
evaluated according to type of P2Y12 inhibitor and patient clinical presentation. A total of
37,964 patients underwent coronary angiography, and 28,306 proceeded to PCI. Pre-
treatment with a P2Y12 inhibitor was observed in 28% and 23% in the overall and PCI
populations, respectively. Moderate variability of pretreatment rates was noted relative to
clinical presentation and P2Y12 inhibitor type. Pretreatment rates remained fairly constant
over time with the exception of a decreasing trend with prasugrel. In conclusion, among
patients referred for invasive evaluation of coronary artery disease, P2Y12 inhibitor pre-
treatment was low in contemporary US practice, an observation consistent over time and
for all available agents and clinical presentations.  2016 The Authors. Published by
Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/). (Am J Cardiol 2016;117:1439e1443)All patients undergoing a percutaneous coronary inter-
vention (PCI) require treatment with a platelet P2Y12 inhibi-
tor.1 PCI usually follows diagnostic coronary angiography in
the same setting (ad hoc PCI), a practice that is followed in
over 80% of PCI performed in the United States and is
endorsed by the Society of Cardiac Angiography and
Interventions.2 The delayed bioavailability of oral P2Y12
inhibitors has prompted the practice of initiating treatment
before coronary angiography (pretreatment) to ensure
that antiplatelet activity would be present should a PCI be
required. Randomized trials comparing pretreatment to
treatment initiated only after the coronary anatomy is deﬁned,
and the decision to proceed with PCI has been made have not
conclusively demonstrated a beneﬁt and have even suggested
possible harm.3,4 In addition, pretreatment may complicate
the process of care for the patients who will require coronary
bypass grafting surgery (CABG) because theywill either have
to experience delays to allow for platelet function to return or
alternatively proceed to surgery at increased bleedingCompany, Parsippany, New Jersey. Manuscript received
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0.1016/j.amjcard.2016.02.012risk. Guideline recommendations vary, with pretreatment
generally considered reasonable in patients with acute coro-
nary syndromes (ACS), except when prasugrel is used.
The most recent noneST-elevation myocardial infarction
guidelines released by the European Society of Cardiology
reﬂect the lack of deﬁnitive data to support universal pre-
treatmente“As the optimal timing of ticagrelor or clopidogrel
administration in NSTE-ACS patients scheduled for an
invasive strategy has not been adequately investigated, no
recommendation for or against pretreatment with these agents
can be formulated. Based on the Comparison of Prasugrel at
the Time of Percutaneous Coronary Intervention or as Pre-
treatment at the Time of Diagnosis in Patients with Non-ST
Elevation Myocardial Infarction (ACCOAST) trial results,
pretreatment with prasugrel is not recommended.”5 We
performed this analysis to describe trends of P2Y12 inhibitor
use in contemporary US practice.
Methods
This study used electronicmedical records from theCerner
Health Facts database (Cerner, Kansas City, Missouri).
Health Facts collects comprehensive, time-stamped clinical
and pharmacy records from approximately 300 hospitals and
hospital-afﬁliated outpatient facilities, of diverse size and
afﬁliation (teaching or nonteaching), throughout the US.
Patient records in this database have been deidentiﬁed in
compliance with the Health Insurance Portability and
Accountability Act. Adults undergoing diagnostic coronaryccess article
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Figure 1. Timing of P2Y12 inhibitor loading dose administration for all patients (Top) and patients who proceeded to PCI (Bottom).
1440 The American Journal of Cardiology (www.ajconline.org)angiography with or without PCI from January 2008 to June
2013 who received a loading dose of clopidogrel (300 or
600mg), prasugrel (60mg), or ticagrelor (180mg) at any time
from 48 hours before the start of procedure up to 6 hours afterwere included. Procedure time was determined using a proxy
of pharmacy dispense times for anesthetics, anxiolytics,
contrast media agents, sedatives, or analgesics (in hierarchical
order) in a similarmanner as has been adopted by the CathPCI
Figure 2. Pretreatment rates of P2Y12 inhibitor over time according to clinical presentation (Left) and agent selection (Right).
Coronary Artery Disease/Trends in P2Y12 Inhibitor Use 1441registry6 and published previously.7 Timing of P2Y12 inhib-
itor administration was calculated according to pharmacy
dispense time of P2Y12 inhibitor and procedure time and was
further divided into 3 periods: >2 hours before, 0 to 2 hours
before, or any time after the start of the procedure. Pretreat-
ment rates (ﬁrst 2 time categories) were evaluated for the
overall study population, but also according to the type of
P2Y12 inhibitor (clopidogrel, prasugrel, or ticagrelor) and
clinical presentation (stable coronary artery disease [SCAD],
noneST-elevation ACS [NSTE-ACS], and ST-elevation
ACS [STE-ACS]). This is a descriptive analysis, without a
prespeciﬁed statistical hypothesis. All analyses were con-
ducted using SAS, version 9.2 (SAS Institute Inc., Cary,
North Carolina).Results
A total of 37,964 patients from 77 hospitals (18, 27, 25,
and 7 hospitals from the 4 census regions8 of the Midwest,
Northeast, South, and West, respectively) met the entry
criteria and were included in the analysis. The patient
breakdown according to clinical presentation was 22,631
(59.6%) with SCAD, 8,885 (23.4%) with NSTE-ACS, and
6,448 (17.0%) with STE-ACS. A total of 28,306 patients
(74.6%) underwent angiography and PCI, whereas 9,658
patients (25.4%) underwent only diagnostic coronary
angiography.
Overall, 27.8% of patients included in this analysis
received pretreatment (14.6% >2 hours, 13.2% within 0 to
2 hours). Although there was moderate variability relative to
P2Y12 inhibitor type, overall, pretreatment was more
frequent in STE-ACS and NSTE-ACS than in SCAD
(Figure 1, Top). Pretreatment rates were also low at 23.1%
in the subgroup of the 28,306 patients that proceeded to PCI
with similar patterns of distribution according to P2Y12 in-
hibitor type or clinical presentation as observed in the
overall study population (Figure 1, Bottom).
Practice patterns remained fairly consistent over time
without important difference in pretreatment rates from
2008 to 2013. This stable pattern of pretreatment over time
was true for all clinical presentations (Figure 2, Left). There
seemed to be a trend toward lower rates of pretreatment over
time with the newer agents, especially prasugrel, but in thecase of clopidogrel pretreatment rates remained stable over
time (Figure 2, Right).
Finally, our analysis showed that clopidogrel had been and
still was the most commonly used P2Y12 inhibitor in this
population and even as recently as 2013 was still used in over
3/4 of patients in this database. The use of prasugrel appeared
to have stabilized at about 13%, whereas the adoption of
ticagrelor appeared to be slowly increasing over time and was
at about 10% by 2013 (Figure 3, Top Left). Consistent with
product labels9e11 and practice guidelines, the use of prasu-
grel and ticagrelor was higher in patients with STE-ACS and
NSTE-ACS (15.6% and 11.8%, respectively) compared with
patients with SCAD (11.6% and 7.3%, respectively;
Figures 3, Top Right and Bottom).Discussion
Despite the universal need for P2Y12 inhibitor therapy in
all patients undergoing PCI, there is clinical equipoise
regarding the optimal timing of treatment initiation.1,5 In
this analysis, more than 70% of patients referred for invasive
evaluation of coronary artery disease did not get a loading
dose of a P2Y12 inhibitor before coronary angiography.
Rates of pretreatment appeared to be modestly higher in
patients presenting with STE-ACS and NSTE-ACS but were
still well below 50% for all time points included in this
analysis and across all the types of P2Y12 inhibitors.
These results suggest that clinical practice patterns are
heavily inﬂuenced by the practical and safety considerations
of administering P2Y12 inhibitors before the coronary
anatomy is deﬁned and the treatment plan is ﬁnalized. The
most obvious consideration is that many of these patients
will not require PCI because they may not have signiﬁcant
coronary artery disease, or if they do, may be best treated
with medical management or CABG. Speciﬁcally, the
number of patients who will eventually undergo PCI after
diagnostic coronary angiography ranges greatly according to
clinical presentation: close to 90% for patients presenting
with STE-ACS,12 approximately 60% for patients with
NSTE-ACS,13 and <50% for patients evaluated for
SCAD.14 It is therefore reasonable to understand why cli-
nicians do not feel comfortable with universal pretreatment
of their patients.
Figure 3. Type of P2Y12 inhibitor selection over time for all patients (Top Left), ACS patients (Top Right) and SCAD patients (Bottom).
1442 The American Journal of Cardiology (www.ajconline.org)Importantly, among those patients who will require
CABG surgery, pretreatment with a long-acting P2Y12 in-
hibitor may complicate their care because they would either
need to wait for 3 to 9 days, depending on the agent used,
until sufﬁcient platelet function is restored or proceed to
surgery at an increased bleeding risk.15,16 In addition to the
safety concerns for either scenario, there are also substantial
economic implications with large increases in hospitaliza-
tion costs.17
Finally, our analysis shows that clopidogrel remains the
most commonly prescribed agent in US practice, whereas
ticagrelor and prasugrel are slowly exhibiting increased use
in patients with ACS. It is possible that the recent avail-
ability of generic clopidogrel may further ensure its domi-
nant position in the future.
Several limitations of this analysis should be considered.
First, procedure times were not captured in the database but
were instead inferred by proxy; a method previously adop-
ted and validated by the National Cardiovascular Data
Registry CathPCI registry.6,7 Second, pharmacy dispense
times were used as proxy for time of P2Y12 administration,
so accordingly, hospitals dispensing drugs directly in the
catheterization laboratory were not included in this analysis.
Third, data included in this analysis are limited to the June
2013 and may therefore underrepresent the current usage of
newer P2Y12 inhibitors. Finally, clinical outcomes were notcaptured in this analysis; and therefore, the clinical signiﬁ-
cance of our ﬁndings remains unknown.
Accordingly, these results should be interpreted in lieu of
the previously mentioned limitations and in the context of
local practice patterns; however, the inclusion of a large
number of hospitals with broad geographic distribution does
add substantial external validity to the results.Disclosures
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